181 related articles for article (PubMed ID: 27941566)
1. Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas.
Rubinsak LA; Cohen C; Khanna N; Horowitz IR; Hanley KZ
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):567-572. PubMed ID: 27941566
[TBL] [Abstract][Full Text] [Related]
2. Folate Receptor α Expression Level Correlates With Histologic Grade in Lung Adenocarcinoma.
Driver BR; Barrios R; Ge Y; Haque A; Tacha D; Cagle PT
Arch Pathol Lab Med; 2016 Jul; 140(7):682-5. PubMed ID: 26599808
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.
Despierre E; Lambrechts S; Leunen K; Berteloot P; Neven P; Amant F; O'Shannessy DJ; Somers EB; Vergote I
Gynecol Oncol; 2013 Jul; 130(1):192-9. PubMed ID: 23558051
[TBL] [Abstract][Full Text] [Related]
4. Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type.
O'Shannessy DJ; Somers EB; Smale R; Fu YS
Int J Gynecol Pathol; 2013 May; 32(3):258-68. PubMed ID: 23518909
[TBL] [Abstract][Full Text] [Related]
5. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
[TBL] [Abstract][Full Text] [Related]
6. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Jakobsen A
Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
[TBL] [Abstract][Full Text] [Related]
7. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers.
O'Shannessy DJ; Somers EB; Wang LC; Wang H; Hsu R
J Ovarian Res; 2015 May; 8():29. PubMed ID: 25971554
[TBL] [Abstract][Full Text] [Related]
8. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
Cocco E; Casagrande F; Bellone S; Richter CE; Bellone M; Todeschini P; Holmberg JC; Fu HH; Montagna MK; Mor G; Schwartz PE; Arin-Silasi D; Azoudi M; Rutherford TJ; Abu-Khalaf M; Pecorelli S; Santin AD
BMC Cancer; 2010 Jul; 10():349. PubMed ID: 20598131
[TBL] [Abstract][Full Text] [Related]
9. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
10. Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents.
Cagle PT; Zhai QJ; Murphy L; Low PS
Arch Pathol Lab Med; 2013 Feb; 137(2):241-4. PubMed ID: 22984810
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
12. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
14. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
[TBL] [Abstract][Full Text] [Related]
15. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
Crane LM; Arts HJ; van Oosten M; Low PS; van der Zee AG; van Dam GM; Bart J
Cell Oncol (Dordr); 2012 Feb; 35(1):9-18. PubMed ID: 21647742
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
17. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
18. Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer.
Makhija S; Sit A; Edwards R; Aufman K; Weiss H; Kanbour-Shakir A; Gooding W; D'Angelo G; Ferrell R; Raja S; Godfrey TE
Gynecol Oncol; 2003 Jul; 90(1):3-9. PubMed ID: 12821334
[TBL] [Abstract][Full Text] [Related]
19. Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy.
Hanley KZ; Horowitz IR; Gordon A; Meisel J; Khanna N
Int J Gynecol Pathol; 2021 Sep; 40(5):501-509. PubMed ID: 33323854
[TBL] [Abstract][Full Text] [Related]
20. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]